0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free structure avoids interest and refinancing obligations, giving ATOS greater financial flexibility as it funds clinical development. This is a meaningful structural advantage for a company with no commercial revenue, although liquidity remains constrained by operating losses.
Pipeline Expansion Beyond Breast CancerExpanding (Z)-endoxifen into rare pediatric diseases broadens the potential addressable market beyond breast cancer. Additional indications could diversify clinical opportunities and create more than one route to future regulatory and commercial success.
Clinical And Scientific ValidationPresentation at major oncology conferences and publication in peer-reviewed journals strengthen the scientific foundation of the lead program. External dissemination can improve credibility with researchers, partners and regulators as development advances.
Bears Say
No Revenue And Worsening LossesATOS has no reported revenue and remains dependent on external funding while losses are worsening. Without a commercial product, sustained spending on development increases the time and capital required to reach breakeven.
Increasing Operating Cash BurnThe accelerating operating cash deficit indicates that ATOS is not self-funding and that development costs are consuming liquidity more rapidly. Persistent burn raises the likelihood of additional financing before the pipeline can generate commercial cash flow.
Shrinking Equity And Funding Dilution RiskThe substantial decline in equity reflects cumulative losses and ongoing cash usage, reducing the balance-sheet cushion available to fund trials. Continued reliance on equity financing could dilute existing holders and constrain strategic flexibility.
Atossa Therapeutics News
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $26.35M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 87 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.075.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in GB:0HJ7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.